Immunocore Holdings presented clinical trial data at the ASCO meeting, with stock benefiting from Trump-era tariffs.
2 reports, 2 independent
Updated Oct 15
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Immunocore Holdings presented clinical trial data at the ASCO meeting, with stock benefiting from Trump-era tariffs.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Dayan provided commentary on Immunocore's ongoing clinical trial at Birmingham.1 source
Immunocore presented clinical trial data at ASCO, noting stock benefits from Trump tariffs.1 source
Keep exploring
The entities involved
-
American Society of Clinical Oncology
organization
Nothing else this week.
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)